Cullinan Therapeutics (NASDAQ:CGEM) Insider Sells $24,510.48 in Stock

February 26, 2026 by InsiderTrades.com

Key Points

CEO Nadim Ahmed sold 13,515 shares at an average price of $14.47 for $195,562.05, trimming his position by about 3.34% to 390,803 shares, according to an SEC filing.
Several other senior insiders also executed sales while CGEM traded down to $14.30 (‑$0.06) on the day, with a market capitalization of about $844.84 million and a 12‑month range of $5.68–$14.68.
Analyst views are mixed but the consensus rating is a “Moderate Buy” with a $29.33 average price target; notable moves include Wedbush raising its target to $34 and several firms cutting ratings.

Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) insider Jennifer Michaelson sold 1,752 shares of the company's stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $13.99, for a total value of $24,510.48. Following the transaction, the insider directly owned 180,225 shares in the company, valued at $2,521,347.75. This trade represents a 0.96% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Jennifer Michaelson also recently made the following trade(s):

On Tuesday, February 24th, Jennifer Michaelson sold 3,601 shares of Cullinan Therapeutics stock. The stock was sold at an average price of $14.47, for a total transaction of $52,106.47.
On Friday, February 20th, Jennifer Michaelson sold 11,742 shares of Cullinan Therapeutics stock. The shares were sold at an average price of $14.08, for a total transaction of $165,327.36.
On Thursday, February 12th, Jennifer Michaelson sold 416 shares of Cullinan Therapeutics stock. The stock was sold at an average price of $12.03, for a total value of $5,004.48.
On Thursday, January 22nd, Jennifer Michaelson sold 4,000 shares of Cullinan Therapeutics stock. The stock was sold at an average price of $12.30, for a total value of $49,200.00.
On Friday, December 19th, Jennifer Michaelson sold 1,345 shares of Cullinan Therapeutics stock. The shares were sold at an average price of $10.01, for a total transaction of $13,463.45.
On Thursday, December 18th, Jennifer Michaelson sold 2,898 shares of Cullinan Therapeutics stock. The shares were sold at an average price of $9.67, for a total transaction of $28,023.66.
On Monday, December 15th, Jennifer Michaelson sold 995 shares of Cullinan Therapeutics stock. The stock was sold at an average price of $11.90, for a total value of $11,840.50.
On Friday, December 12th, Jennifer Michaelson sold 2,148 shares of Cullinan Therapeutics stock. The shares were sold at an average price of $12.38, for a total value of $26,592.24.

Cullinan Therapeutics Stock Down 1.1%

Shares of CGEM traded down $0.17 on Thursday, hitting $14.20. The company's stock had a trading volume of 298,440 shares, compared to its average volume of 718,483. The firm's fifty day moving average price is $11.50 and its 200-day moving average price is $9.31. Cullinan Therapeutics, Inc. has a fifty-two week low of $5.68 and a fifty-two week high of $14.68. The firm has a market capitalization of $838.64 million, a price-to-earnings ratio of -4.29 and a beta of -0.09.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Invesco Ltd. increased its position in Cullinan Therapeutics by 27.4% in the 4th quarter. Invesco Ltd. now owns 130,323 shares of the company's stock valued at $1,349,000 after acquiring an additional 28,011 shares during the period. Virtus Investment Advisers LLC grew its holdings in Cullinan Therapeutics by 75.5% in the fourth quarter. Virtus Investment Advisers LLC now owns 22,318 shares of the company's stock worth $231,000 after purchasing an additional 9,604 shares during the period. Susquehanna Portfolio Strategies LLC boosted its position in shares of Cullinan Therapeutics by 87.8% during the 4th quarter. Susquehanna Portfolio Strategies LLC now owns 233,842 shares of the company's stock worth $2,420,000 after purchasing an additional 109,311 shares in the last quarter. Elmind Capital LP acquired a new stake in shares of Cullinan Therapeutics in the 4th quarter valued at about $3,208,000. Finally, Engineers Gate Manager LP increased its position in Cullinan Therapeutics by 37.7% in the 4th quarter. Engineers Gate Manager LP now owns 69,343 shares of the company's stock valued at $718,000 after buying an additional 18,980 shares in the last quarter. Institutional investors own 86.31% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on CGEM. Wall Street Zen cut shares of Cullinan Therapeutics from a "hold" rating to a "sell" rating in a research report on Sunday, February 8th. Zacks Research cut shares of Cullinan Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Thursday, February 19th. Guggenheim assumed coverage on shares of Cullinan Therapeutics in a report on Monday, February 2nd. They issued a "buy" rating and a $30.00 price objective on the stock. HC Wainwright increased their target price on shares of Cullinan Therapeutics from $26.00 to $27.00 and gave the stock a "buy" rating in a report on Thursday, January 8th. Finally, Citigroup began coverage on shares of Cullinan Therapeutics in a research report on Tuesday, February 17th. They issued a "buy" rating and a $33.00 target price for the company. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $29.33.

View Our Latest Analysis on CGEM

Trending Headlines about Cullinan Therapeutics

Here are the key news stories impacting Cullinan Therapeutics this week:

Positive Sentiment: Reported short interest shows 0 shares outstanding as of Feb. 25 — if accurate, near-zero short interest reduces potential forced selling from shorts and can cap downside pressure. Read More.
Neutral Sentiment: Analyst coverage is mixed but tilted positive on balance: consensus is a "Moderate Buy" with a long-run average price target substantially above the current quote, while a few shops have trimmed ratings recently — this creates both upside narrative and dispersion in expectations. Read More.
Neutral Sentiment: Macro risk-on flows may be softer (noted crypto weakness), which can pressure small/biotech names generally but is not company-specific. Read More.
Negative Sentiment: CEO Nadim Ahmed sold 13,515 shares at an average $14.47 (≈$195.6k), trimming his stake by ~3.34%; multiple recent sales by the CEO may be viewed negatively by investors as signaling insider monetization. Read More.
Negative Sentiment: Other senior insiders also sold on Feb. 24: Jeffrey Alan Jones (4,582 shares) and Jacquelyn L. Sumer (3,601 shares) at the same ~$14.47 price — these coordinated/clustered sales amplify perception of insider cashing out. Read More. • Read More.
Negative Sentiment: Director/executive Jennifer Michaelson executed two recent sales (3,601 shares at $14.47 on Feb. 24 and 1,752 shares at $13.99 on Feb. 23), further trimming insider holdings. Read More.

About Cullinan Therapeutics

(Get Free Report)

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.